Clinical trials: GI Disorders
Celiac Disease
Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.
The purpose of this study is to evaluate the safety of different amounts of BL-7010 in single oral administration and in repeated oral administration to well-controlled celiac patients.
- Trial name
- NCT01990885
- Testing
- BL-7010
- Where
- 2 sites in Finland
- Volunteers
- 40 people
- Sponsor
- BioLineRx, Ltd.
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Eosinophilic Esophagitis (EoE)
Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis
This study aims to introduce a new dietary therapy for Eosinophilic Esophagitis (EoE) patients by using partial enteral nutrition (PEN) to enhance remission rates and explore how this approach affects immune function, gut…
- Trial name
- NCT07234825
- Testing
- Partial enteral nutrition (PEN) with dairy elimination, Dairy elimination alone
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Kate Farms Inc
Recurrent Ovarian Cancer, HER2-negative
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
- Conditions
- Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC
- Trial name
- HS-10502 (NCT06769425)
- Testing
- HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer
Pan-tumor MRD Study
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors.
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer)
- Trial name
- NCT06605404
- Testing
- blood and tissue samples
- Where
- 47 sites in United States
- Volunteers
- 1,350 people
- Sponsor
- Paradigm Health
Irritable Bowel Syndrome
Fructo-oligosaccharides and Irritable Bowel Syndrome
Fructo-oligosaccharides are known as prebiotic ingredients to modulate the composition of the intestinal microbiota and particularly to stimulate the growth of Bifidobacteria.
- Trial name
- NCT00806104
- Testing
- Fructo-oligosaccharides, Maltodextrins
- Where
- 2 sites in France, Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Beghin-Meiji
Esophageal Cancer, Gastric Cancer
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally…
- Trial name
- NCT00005876
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Ulcerative Colitis
Open-label V565 Target Engagement Study
The purpose of the study is to confirm that V565 enters inflamed tissue, binds to TNF and reduces inflammation after oral dosing to patients with IBD.
- Trial name
- NCT03705117
- Testing
- V565
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- VHsquared Ltd.
Crohn Disease
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.
- Trial name
- NCT03467958
- Testing
- Ozanimod
- Where
- 766 sites in United States, Argentina and 47 more
- Volunteers
- 854 people
- Sponsor
- Celgene
Pulmonary Embolism, Medical Device Complication
Angel® Catheter Post Market Registry
This is a post-market, observational, retrospective multi-center Registry designed to gather information on the performance of the Angel® Catheter in general clinical practice.
- Conditions
- Pulmonary Embolism, Medical Device Complication, Deep Vein Thrombosis, Catheter Thrombosis
- Trial name
- NCT02917135
- Testing
- Angel® Catheter
- Where
- 5 sites in Germany, Italy and 1 more
- Volunteers
- 2,000 people
- Sponsor
- BiO2 Medical
Colitis, Ulcerative
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
The purpose of this real world non-interventional study is to learn about the effects of etrasimod as treatment for patients with moderate to severe ulcerative colitis.
- Trial name
- EFFECT-UC (NCT06294925)
- Testing
- Etrasimod
- Where
- 41 sites in Canada, Germany and 1 more
- Volunteers
- 360 people
- Sponsor
- Pfizer
Short Bowel Syndrome
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF
The primary objective of the trial is the confirmation of the efficacy of apraglutide to evaluate the efficacy of weekly subcutaneous apraglutide in reducing parenteral support dependency.
- Trial name
- STARS (NCT04627025)
- Testing
- apraglutide
- Where
- 68 sites in United States, Argentina and 16 more
- Volunteers
- 164 people
- Sponsor
- VectivBio AG
Colon Cancer, Rectal Cancer
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy plus ramucirumab, or standard…
- Trial name
- NCT01111604
- Testing
- Ramucirumab, Icrucumab, mFOLFOX-6
- Where
- 17 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Eli Lilly and Company
Rotaviral Gastroenteritis
Study to Estimate the Disease Burden of Acute Rotavirus Gastroenteritis in Children < 5 Years in United Arab Emirates
The purpose of this study is to estimate the disease burden and epidemiology of rotavirus gastroenteritis in children less than 5 years of age, in United Arab Emirates.
- Trial name
- NCT01201252
- Testing
- Stool sampling
- Where
- 3 sites in United Arab Emirates
- Volunteers
- 717 people
- Sponsor
- GlaxoSmithKline
Cancer, Colon Cancer
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
This is a multi-center, open-label, randomized, phase 2, two-arm clinical trial to be conducted in the United States. Approximately 210 eligible KRAS wild-type expressing metastatic colorectal cancer subjects who have failed…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Metastatic Cancer
- Trial name
- NCT00418938
- Testing
- Panitumumab, Bevacizumab, Leucovorin
- Volunteers
- 266 people
- Sponsor
- Amgen
Inflammatory Bowel Disease, Colitis, Ulcerative
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)
The purpose of this study is to evaluate the clinical effectiveness (how well the treatment works) of Guselkumab, by lines of treatment and subpopulations, and what are the outcomes of treatment (clinical outcomes) in adult…
- Conditions
- Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn's Disease
- Trial name
- GUSTO-UK (NCT07242248)
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Janssen-Cilag Ltd.
Irritable Bowel Syndrome
A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679
To better understand the way that GW876008 and GSK561679 work on hormone responses in patients with Irritable Bowel Syndrome.
- Trial name
- NCT00511563
- Testing
- GW876008 and GSK561679
- Sponsor
- GlaxoSmithKline
Colorectal Cancer
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer that has recurred after previous treatment and that cannot be safely removed by surgery or has spread…
- Trial name
- NCT07775287
- Testing
- Petosemtamab, Cetuximab, Bevacizumab
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- Genmab
Colorectal Cancer Screening, Colorectal Cancer
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
This is a prospective longitudinal study to assess the impact of repeat Cologuard testing at 3 years in average risk patients.
- Trial name
- NCT02419716
- Testing
- Cologuard
- Where
- 40 sites in United States
- Volunteers
- 2,404 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Idiopathic Gastroparesis
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects.
- Trial name
- NCT06899217
- Testing
- CIN-102 Dose 15mg, CIN-102 Dose 10mg
- Where
- 85 sites in United States
- Volunteers
- 416 people
- Sponsor
- CinDome Pharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.